An Open-Label, Randomized, Single Dose Crossover Study to Determine the Bioequivalence of Duodart 0.5mg/0.4mg (Capsule Formulation of Dutasteride 0.5mg and Tamsulosin Hydrochloride 0.4mg) Compared to Concomitant Dosing of Avodart 0.5mg and Omnic 0.4mg Commercial Capsules in Healthy Male Subjects.

Trial Profile

An Open-Label, Randomized, Single Dose Crossover Study to Determine the Bioequivalence of Duodart 0.5mg/0.4mg (Capsule Formulation of Dutasteride 0.5mg and Tamsulosin Hydrochloride 0.4mg) Compared to Concomitant Dosing of Avodart 0.5mg and Omnic 0.4mg Commercial Capsules in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Dutasteride/tamsulosin (Primary) ; Dutasteride; Tamsulosin
  • Indications Benign prostatic hyperplasia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Oct 2012 Planned End Date 1 Nov 2012 added as reported by ClinicalTrials.gov.
    • 26 Oct 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top